New research questions emerge as medical needs continue to evolve and as we improve our understanding of cancer biology and treatment of malignancies. Although significant advances have been made in some areas of breast cancer research resulting in improvements in therapies and outcomes over the last few decades, other areas have not benefited to the same degree and we continue to have many gaps in our knowledge. This article summarizes the 12 short and medium-term clinical research needs in breast cancer deemed as priorities in 2016 by a panel of experts, in an attempt to focus and accelerate future research in the most needed areas: (i) de-escalate breast cancer therapies in early breast cancer without sacrificing outcomes; (ii) explore optimal adjuvant treatment durations; (iii) develop better tools and strategies to identify patients with genetic predisposition; (iv) improve care in young patients with breast cancer; (v) develop tools to speed up drug development in biomarker-defined populations; (vi) identify and validate targets that mediate resistance to chemotherapy, endocrine therapy and anti-HER2 therapies; (vii) evaluate the efficacy of local-regional treatments for metastatic disease; (viii) better define the optimal sequence of treatments in the metastatic setting; (ix) evaluate the clinical impact of intra-patient heterogeneity (intratumor, inter-tumor and inter-lesion heterogeneity); (x) better understand the biology and identify new targets in triplenegative breast cancer; (xi) better understand immune surveillance in breast cancer and further develop immunotherapies; and (xii) increase survivorship research efforts including supportive care and quality of life.
Introduction
As substantial progress continues to be made in cancer biology, technology and treatment, medical needs evolve, resulting in the emergence of new research questions. In addition, while some areas have benefited from rapid advances in the last decades, substantial progress has been lacking in other areas and we continue to lack data that would improve our understanding of common problems and lead to improved therapies. Several key research needs are global and encompass all tumor types [1] . This article focusses on the issues specific to breast cancer, and will present the research needs currently deemed as priorities by experts in the field, and attempt to focus and accelerate future research in the most needed areas.
Breast cancer is the most common cancer overall among women in both developed and less developed regions of the world, representing 25% of new cancer cases among women, and the second cause of death in developed regions after lung cancer [2] . Despite its increasing incidence, breast cancer mortality has been decreasing in most high-income countries of Europe and North America due to screening, early detection and access to adjuvant treatments [3, 4] . Indeed, screening programs are estimated to have reduced breast cancer mortality by 20% in the invited population [5, 6] . In addition, breast cancer is one of the fields in oncology that has seen some major advances in the understanding of the underlying biology with the molecular characterization into distinct entities, as well as changes in terms of treatment and prognosis in the last 15 years, as illustrated by the use of trastuzumab for the adjuvant treatment of women with human epidermal growth factor receptor 2 (HER2)-overexpressing early-stage and advanced breast cancer [7] and the development of new modalities of endocrine therapy, in particular aromatase inhibitors (AI) [8] . While these advances have improved patient outcomes, some forms of the disease continue to be resistant to current treatments or remain poorly understood, and some issues directly impacting patients' well-being have not been sufficiently addressed. Furthermore, both incidence and mortality from breast cancer are increasing in developing regions of the world where significant challenges remain.
In order to define the current research needs in breast cancer, a panel of 13 experts from 11 countries discussed over two teleconferences and identified 12 short-term clinical research priorities ( Table 1 ). The background and rationale for accelerating research are presented for each topic. The present article was discussed and circulated to all panel members by email for comments and corrections.
De-escalate breast cancer therapies in early breast cancer without sacrificing outcomes While adjuvant chemotherapy has been shown to reduce 10-year breast cancer mortality for all subtypes by one-third compared with no chemotherapy [9] , patients who are at low-risk for recurrence derive a small absolute benefit which may be outweighed by long-term toxicities, such as cardiotoxicity, leukemia, cognitive function and neurotoxicity [10] . Likewise, although post-operative radiation therapy reduces the risk of local recurrence and improves survival [11, 12] , it also increases the risk of cardiovascular diseases and secondary malignancies, although these risks are reduced with modern techniques [13, 14] . Surgical treatment of primary breast cancer has been de-escalated over the last decades, with breastconservation surgery and sentinel lymph node biopsy being increasingly performed over mastectomy and axillary lymph node dissection, resulting in equivalent or superior survival outcomes in certain settings [15, 16] . The possibility to continue to de-escalate both systemic and local-regional treatments, particularly radiation therapy, needs to be further investigated in order to tailor treatment to each patient according to anatomy and specific tumor biology, avoiding unnecessary side effects as well as containing costs.
Results from four prospective trials have been or will shortly be reported, that aim to validate genomic tools to guide clinical decision-making on adjuvant chemotherapy in patients with early breast cancer. The MINDACT study assesses the clinical utility of the Amsterdam 70-gene profiler (MammaPrint V R ) in addition to traditional clinico-pathological factors in identifying early breast cancer patients at sufficient low risk, for whom adjuvant chemotherapy can be safely omitted. Without chemotherapy, DMFS (distant-metastasis free survival) of 95% at 5 years, was achieved in both node-negative and node-positive estrogen receptor (ER)-positive/HER2-negative patients [17] . The large TailorX study has recently reported on the low-risk cohort and shown the validity of a 21-gene expression assay (Oncotype DX V R ) in identifying these women with ER-positive, HER2-negative, node-negative disease at low-risk for recurrence who could be spared chemotherapy and treated with endocrine therapy alone [18] . Data is pending on the randomized cohort in the intermediate range of the Oncotype test and is of more interest in terms of avoiding chemotherapy. The RxPONDER study uses the same assay but addresses women with one to three positive nodes, and has completed enrollment but has not yet been reported [19] . The West German Study Group (WSG) PlanB trial used Oncotype DX prospectively in over 3000 node-negative and node-positive patients with ER-positive, HER2-negative disease for indication for chemotherapy. Among patients with 0-3 involved lymph nodes, chemotherapy was omitted in 15.3% with low-risk recurrence score. An excellent 3-year disease-free survival (DFS) rate of 98% was observed with adjuvant endocrine therapy alone in these patients [20] . The WSG ADAPT study is currently evaluating whether adjuvant chemotherapy can also be omitted in the intermediate risk group after good proliferation response to 3-week preoperative endocrine therapy [21] . The combined results of these trials are likely to better delineate which low-risk cancers may or may not benefit from the addition of chemotherapy to adjuvant hormonal therapy, and expand the proportion of patients who can be safely treated without chemotherapy.
As for HER2-positive disease, the administration of adjuvant paclitaxel and trastuzumab has been considered for patients with small tumors (<3 cm), with less toxic effects than standard adjuvant regimens [22] . Continued efforts are needed to further deescalate management of early breast cancer in those who do not need the more aggressive approaches. New prognostic and predictive biomarkers should be developed [23] with the aim of delivering optimal treatments with minimal side effects. New study designs and level of evidence scales should be initiated in order to approve biomarkers for treatment de-escalation. The challenge is to lobby for independent governmental and academic sources of funding for studies that aim for treatment de-escalation and to set up studies of the size necessary to show non-inferiority. For radiotherapy, biomarkers for radio-sensitivity or radio-resistance should be developed to minimize harms [24, 25] and to prescribe this therapy only to those patients who benefit from it. Trials that identify women who can safely undergo breast conservation without radiation are needed, given the preponderance of breast cancer in older women. In addition, given the significant proportion (60-70%) of early disease HER2-positive patients who are cured with adjuvant chemotherapy alone without the addition of anti-HER2 agents, identifying these patients that may not require the more expensive therapies and that can be adequately treated with more standard approaches would have a significant impact particularly in low-and middle-income countries.
Explore optimal adjuvant treatment durations
Endocrine treatment is one of the cornerstones of breast cancer treatment, but its optimal duration in the adjuvant setting continues to be debated. Endocrine therapy for a total duration of 10 or even up to 15 years is now recommended over 5 years, either with tamoxifen alone, tamoxifen followed by AIs or vice-versa, or AIs alone [26, 27] . However, only a proportion of patients actually benefit from prolonged endocrine therapy and these recommendations should be tailored to the risk of the cancer recurring and the toxicity of the treatments. Biomarkers of late recurrences are urgently needed.
The standard treatment for HER2-targeted therapy with trastuzumab is 1 year in early breast cancer; however, given the development of resistance to trastuzumab in some patients as well as its cost and cardiotoxicity [14] , it is worth exploring different treatment durations. The HERA trial of trastuzumab reported that a longer duration (2 years) did not improve outcomes, but had higher secondary cardiac events, and should not be recommended [28] . Following promising results from the FinHER trial that showed improvement with only 9 weeks of trastuzumab [29] , several trials were set up to explore shorter trastuzumab treatment durations. Although the PHARE trial failed to show the non-inferiority of 6 months versus 1 year of adjuvant trastuzumab [30] , results from other studies comparing 3 or 6 months of trastuzumab versus 1 year are awaited [31, 32] . Another unresolved issue is the duration of trastuzumab maintenance therapy in advanced breast cancer patients who achieve a complete response, as well as the number of lines of therapy for advanced disease that should include anti-HER2 agents.
As illustrated with tamoxifen, AIs, and trastuzumab, the question of optimal treatment duration arises with every agent and affects survival, quality of life and costs, for both high-and low/ middle-income countries [33] . The possibility to investigate different durations should be integrated in the design of adjuvant clinical trials, in order to have timely information on the optimal duration. One possible way to decrease treatment duration could be to select patients eligible for shorter treatment based on stage, biomarkers, and pathological complete response (pCR) to neoadjuvant therapy, which has been described to be associated with improved outcome [34] , or other surrogates such as tumorinfiltrating lymphocytes (TILs), currently under investigation [35] . Using in vivo response assessment, it needs to be evaluated whether patients achieving a pCR to neoadjuvant anti-HER2 treatment still require completion of 1 year of anti-HER2 therapy after surgery.
Studying the safety of omitting post-mastectomy radiation after an excellent response to neoadjuvant therapy is also relevant. For the time being, the extent of radiation is determined by the stage pre-neoadjuvant systemic therapy. There is a need to evaluate if it can be guided by the stage post-neoadjuvant therapy.
Develop better tools to identify patients with genetic predisposition
Despite the identification of a number of breast cancer susceptibility genes in the last decades (e.g. TP53, PTEN, CDH1, STK11, CHEK2, ATM, BRIP1, PALB2), genetic testing for patients with suggestive family history has predominantly focused on the two major susceptibility genes, BRCA1 and BRCA2. In addition, family risk is unexplained by a single known gene mutation in >70% of patients with family history, indicating that there are likely to be many more genetic variants and triggers to be identified, each of which accounting for a small fraction of the familial risk [36] . Confirmation of genetic predisposition can promote implementation of risk reduction strategies, including close surveillance (self-examination, bi-annual clinical breast examinations, annual MRI or mammography), prophylactic salpingo-oophorectomy, prophylactic mastectomy, and medical prevention with selective estrogen receptor modulators or AIs, depending on the individual's estimated risk and preferences [37] .
Further work is necessary not only to identify new susceptibility genes to complete the picture, but also to effectively screen women with family history and to conceive appropriate management interventions in persons with a positive test to one of the numerous susceptibility genes conferring different levels of risk. New genetic testing options have recently become available, such as the Hereditary High-Risk Breast Cancer Panel, which includes six high-penetrance genes and PALB2, and the BROCA assay, a panel of 49 genes including high, moderate and low-penetrance genes [38] . The use of new genetic testing tools must be accompanied by appropriate interpretation of results and variants, however, in order for results to be applicable in clinical decision-making, especially regarding common, low-penetrance genes. In addition, optimal surveillance and prevention strategies should be investigated for high-risk patients in terms of survival benefits.
For BRCA1/2 mutation carriers who develop breast cancer, the treatment choice has been based on histology, subtype and stage, as with sporadic breast cancer, but recent studies show that Poly(ADP-Ribose) Polymerase (PARP) inhibitors may be effective in the treatment of tumors harboring BRCA1/2 mutations [39] . Identification of additional agents may improve treatment and prognosis of patients with hereditary breast cancer. As well, understanding the natural history of the tumors associated with susceptibility genes is important and remains a gap in our knowledge particularly with estrogen-sensitive tumors. Research into association of genetic predisposition and triggers of malignant transformation also deserves more attention.
Improve care in young patients with breast cancer
Young women with breast cancer often have cancer diagnoses at a more advanced stage and of more aggressive subtypes resulting in poorer prognosis. Although some biological features of the tumor may be unique to young patients [40] , it is still unclear whether young patients truly benefit from a more aggressive adjuvant approach [41] , and current guidelines recommend that the choice of treatment should be based on the stage and biology of the tumor and not on age alone, both in the early and advanced settings. Guidelines suggest that women should not be overtreated on the basis of young age alone [42] ; however, there is a paucity of data on the safety of treating very young women with potentially endocrine responsive tumors without adjuvant chemotherapy [18, 43] . In addition, some aspects of breast cancer in young patients are indeed specific to their age and stage in life, such as fertility, genetics, psychosocial concerns and long-term side-effects and require specific management and long-term follow-up.
As evidence is lacking to warrant specific clinical management recommendations for the young age group, more research is needed to better understand the molecular characteristics of breast cancer in young women. Next-generation sequencing (NGS) should facilitate the characterization of mutations in tumors found in young women, and the identification of potential targets. In this regard, the D-Beyond trial is currently evaluating the effect of short-term use of pre-operative denosumab, a RANKL (receptor activator of nuclear factor-kB ligand) inhibitor, in young women (premenopausal) with breast cancer based on gene expression profiling data that showed high expression of RANKL in tumors arising in young women [44] . Prospective clinical trials are needed to determine the most appropriate treatment and whether more aggressive adjuvant therapies have any impact on survival.
Given their longer life expectancy, quality of life (QoL) is an especially critical issue for young breast cancer survivors. Potential long-term toxicities of chemotherapy and endocrine therapy include cardiovascular diseases, cognitive dysfunction and bone loss, which can seriously and permanently affect their QoL. Deescalation in terms of both intensity and duration of treatments including ovarian suppression is particularly relevant for the young, lower risk patients. Furthermore, only limited data are available on different aspects of the safety of fertility preservation methods and pregnancy after breast cancer. Improved fertility preservation strategies are needed for young patients wishing to have biological children after treatment. Efforts are also needed to improve interaction between oncologists and fertility specialists, for counseling on infertility risks and fertility preservation options in a timely manner, before the onset of any anticancer therapy [45] .
Develop tools to speed up drug development in biomarker-defined populations
Studies in the past decade have shown that breast cancer is a heterogeneous disease comprising a multitude of rare genomic anomalies [46, 47] , which could represent potential targets for therapy. While 15-20% of women who develop early breast cancer have HER2 amplification, most genomic alterations are much less frequent, occurring in <1-10% of breast cancer patients. Although a targeted therapy may be effective in a small subset of patients, the treatment effect may be diluted if tested in an unselected population. On the other hand, it is a challenge to conduct clinical trials for each rare anomaly and the mere patient accrual time and sample size needing to be screened may be prohibitive. Innovative clinical trial designs are needed to demonstrate a drug's efficacy and validate biomarkers of response in a short period of time.
Future clinical trials should be newly designed (i) to have drugs developed and approved even based on a small group of patients, as long as properly selected; and (ii) to have predictive biomarkers validated in parallel with drug development and approval. Some innovative clinical trial designs are being implemented to overcome the challenges posed by the molecular diversity of breast cancer and accelerate drug development [48, 49] . Earlier endpoints can be considered for faster assessment of treatment efficacy, such as pCR in the neoadjuvant setting for certain breast cancer subtypes [34] , but efforts should continue to ascertain the impact of new therapies on long-term outcomes, even after initial approval. Robust tools to screen patients are needed for biomarker identification and validation, such as liquid biopsy and NGS, along with standardization of biomarker assessment methods. In addition, initiatives such as Project GENIE [50] , an international database on genomic data and clinical outcomes including rare cancers and rare variants of cancer, may facilitate implementation of clinical trials and drug approval even based on a small number of patients, by providing historical control data for control arms and increased statistical power.
Identify and validate targets that mediate resistance to chemotherapy, endocrine therapy and anti-HER2 therapies
Although contemporary systemic treatments have improved survival outcomes, many breast cancer patients develop resistance both prior to treatment (innate) or following exposure (acquired) to chemotherapy, endocrine therapy (tamoxifen, AIs or fulvestrant), or anti-HER2 therapy. Resistance to chemotherapy remains common, and is a major cause of relapse, though how individual patients will respond to different chemotherapeutic agents is difficult to predict. Although endocrine therapy is a very effective treatment for ER-positive disease, a proportion of women treated with endocrine therapy in the adjuvant setting and all those treated in the metastatic setting eventually progress.
About 15% of patients with HER2-positive cancers relapse after adjuvant trastuzumab and eventually metastatic patients develop resistance to anti-HER2 agents [51] . Various pathways and crosstalks between pathways have been investigated to date, which could be involved in the development of resistance. Further elucidation of mechanisms of resistance is needed to better identify patients who will develop resistance, and to overcome resistance through other targets.
One example is the targeting of PI3K pathway in HER2-positive breast cancer resistant to trastuzumab based on preclinical evidence that mTOR inhibition restored sensitivity to trastuzumab in PTEN-deficient breast cancer cell lines [52] . Results from recent studies did not formally show clinical benefit of adding everolimus, an mTOR inhibitor, to trastuzumab and chemotherapy [53, 54] , but indicated that combined targeting of hormone receptors, HER2, and the PI3K pathway may be a promising strategy. Results are awaited from ongoing trials that are investigating the efficacy of such combined therapies (PI3K/ mTOR inhibitor, endocrine therapy and HER2-targeted therapy) in HER2-resistant breast cancer. Likewise, in ERþ disease that develops resistance to endocrine therapy, mTOR inhibitors and CDK4/6 inhibitors may improve its efficacy [55, 56] . Given the potential short-and long-term toxicities associated with each type of treatment, efforts must continue to find novel agents and ways to avoid ineffective treatments for many months or years without any clinical benefit, through identification of biomarkers of response. Clinically, resistance may present as residual tumor to standard neoadjuvant therapy; better adjuvant therapy approaches are urgently needed for non-pCR patients, in particular in HER2-positive and triple-negative disease.
Evaluate the efficacy of local-regional treatments for metastatic disease
For locally advanced and metastatic cancer, systemic therapy is usually the main treatment, and contemporary, more effective treatments have improved survival [57, 58] . The clinical benefit of local-regional treatment of the primary tumor with surgery and radiation therapy in patients with metastatic disease is still debated. Most data that support the surgical removal of the primary tumor come from retrospective studies and may be subject to selection bias [59] [60] [61] , and evidence from prospective, randomized trials remains controversial.
Several ongoing, prospective, randomized controlled trials are investigating the effect of surgical removal of primary breast tumor on survival of metastatic breast cancer patients [62] [63] [64] . One recently published study reported no survival benefit with localregional treatment of the primary tumor in metastatic breast cancer [65] , but the question remains open with the development of improved systemic therapies and imaging techniques to detect metastases at an early stage, that some patients with favorable prognostic factors and limited metastatic spread may indeed benefit from surgery. As for management of metastases, the choice of local therapy may be particularly important in oligometastatic disease, which is characterized by single or few detectable metastatic lesions that are usually limited to a single organ, and is potentially amenable to long-term complete remission [66] . Further work is needed to establish evidence-based recommendations on the management of distant metastases, namely brain, bone, liver and lung [67, 68] .
Newer techniques, such as radiosurgery and radiofrequency ablation, are increasing local-regional treatment options for unresectable metastases. Moreover, the efficacy of regional or intrathecal trastuzumab is also being explored. Future advances will likely come from the combination of improved systemic therapies and local therapy techniques.
Better define the optimal sequence of treatments in the metastatic setting
In contrast to early breast cancer and frontline metastatic disease, guidelines for treatments after first-line metastatic therapies have been difficult to develop [67, 69] . Although the survival of metastatic breast cancer patients has been improving over the years, the median overall survival remains at 2-3 years, although this is widely variable among subtypes [69, 70] . There is a need to identify the optimal treatment for metastatic breast cancer patients to prolong survival while maintaining QoL, but clinical trial designs are often limited by the necessity of restricting the eligibility to patients with a specific previous treatment or those who have not received previous treatment. For many treatments and situations, especially later lines of therapy, data is lacking to support evidence-based recommendations. New, better suited endpoints, with verified clinical relevance, are urgently needed to correctly evaluate the added value of each treatment of approach.
Better-designed, preferably biomarker-based and risk-based prospective randomized controlled trials are needed to define the optimal sequence or combination of therapies in the metastatic setting. Given the different lines of treatments metastatic breast cancer patients have received and the different resistance profiles, we need to develop a strategy to effectively address several possible combinations or sequences of treatments in clinical trials. Novel agents as well as combinations of novel agents with existent therapies should be investigated. This will require better models of collaboration between academics and all the different pharmaceutical companies involved, as well as independent sources of funding. For ER-positive, HER2-negative disease, novel agents are currently in development or available as first-line, or following endocrine therapy, or in combination with endocrine therapy, such as CDK4/6 inhibitor, PI3K inhibitors, mTOR inhibitor, and histone deacetylase inhibitor [71] . For HER2-positive disease, the optimal sequence or combination of different available HER2-targeted therapies should be explored (trastuzumab, pertuzumab, trastuzumab emtansine, lapatinib, neratinib). Rational design of sequencing studies should take into account the diagnosis of specific resistance mechanisms that may arise as a consequence of previous therapies. Indeed, managing metastatic breast cancer years after the initial diagnosis on the basis of the initial primary tumor characteristics does not make biological sense. The issue of re-biopsies and liquid biopsies should be incorporated in the design of future trials.
Evaluate the clinical impact of intra-patient heterogeneity (intra-tumor, inter-tumor and inter-lesion heterogeneity)
While breast cancer is routinely classified into subtypes according to histology and immunohistochemistry to determine treatment, it has been appreciated in recent years that tumor heterogeneity exists at the morphological and molecular levels within a tumor (intra-tumor), between tumors (inter-tumor), between primary tumor and metastasis or between metastases of the same tumor (inter-lesion) [72] . In addition to spatial heterogeneity at a given time, tumors can also evolve during disease progression (temporal heterogeneity), which may underlie the development of resistance to prior treatment. In addition, every administered therapy undoubtedly induces a change in the biology of the tumor. Tumor heterogeneity calls into question the current clinical decision-making based on the presence or overexpression of molecular markers, usually from a single biopsy and very often from the primary tumor.
In order to accurately assess molecular markers across time and space, biopsies may be performed at multiple sites of the tumor and at relapse or progression from multiple metastatic sites. However, multiple and several biopsies are cumbersome and affect the QoL of patients. Further work is needed to develop and validate non-invasive techniques to capture the patient's tumor genetics and dynamics. Liquid biopsy using circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) is currently in development, and will likely become a valuable tool to assess prognosis, select patients for targeted therapies, detect recurrence and resistance, and evaluate response to therapies [73] . Emerging imaging modalities [74] and mathematical models [75, 76] also present new ways to quantify tumor heterogeneity or predict tumor evolution. Most importantly, we need to understand the clinical impact of tumor heterogeneity, namely, whether it is related to poor prognosis and resistance to therapy, and how the results indicating tumor heterogeneity should guide treatment decision [77] .
Better understand the biology and identify new targets in triple-negative breast cancer Triple-negative breast cancer (TNBC) is characterized by lack of significant expression of ER, Progesterone Receptor (PR), and HER2 Receptors. TNBC accounts for 15% of all breast cancers. By definition, these tumors do not respond to endocrine therapy or HER2-targeted agents, and cytotoxic chemotherapy remains the main effective systemic therapy. TNBC patients have a poorer overall prognosis compared with other subtypes due to a high risk of recurrence and aggressive disease course. There is a major need for new treatment options and effective targeted therapies. Due to considerable heterogeneity within the TNBC subtype in terms of histological and molecular characteristics, it most likely comprises several subtypes that are in the process of being identified.
Ongoing basic research on tumor biology is crucial to find new cancer pathways and new potential targets, which may not necessarily be specific to TNBC but may lead to better treatment outcomes. Molecular profiling may better define the additional subtypes within TNBC [78] and lead to identification of actionable targets. Given the heterogeneity within TNBC, it is unlikely that one agent will suit all TNBC patients; the development of novel targeted agents should therefore be carried out simultaneously with that of companion biomarkers. Ongoing trials are investigating a number of new targeted agents in TNBC, including PARP inhibitors, androgen receptor inhibitors and PI3K pathway inhibitors [79, 80] , as well as immune checkpoint inhibitors (see 'Better understand immune surveillance in breast cancer and further develop immunotherapies' section). An emerging and promising treatment modality is the expression of targets for antibody-drug conjugates (ADC) [81] . Biomarkers that are specific to TNBC that would enable effective and specific drug delivery by ADC are urgently needed.
Better understand immune surveillance in breast cancer and further develop immunotherapies
In the cancer state, the immune system that would normally recognize and attack cancer cells is held back by immunosuppressive mechanisms. One recently developed immunotherapy approach consists of inhibiting immune checkpoints and triggering an antitumor immune response. Immune checkpoint inhibitors such as anti-CTLA4 (cytotoxic T lymphocyte associated protein 4) and anti-PD-1 (programmed death 1)/PD-L1 (programmed death ligand 1) monoclonal antibodies have been shown to induce durable cancer regression, particularly in melanoma, non-small cell lung cancer and renal cell carcinoma. Other checkpoint inhibitors are being actively investigated [82] . In breast cancer, preliminary results of phase I trials of anti-PD-L1 in metastatic breast cancer have shown encouraging results [83] . It needs to be investigated which is the preferred delivery of immune therapy in breast cancer, as single agents or together with chemotherapy.
Immunotherapy represents a promising treatment modality that warrants further research in breast cancer, especially in TNBC for which effective treatments are lacking. The role of the immune response needs to be investigated in different breast cancer subtypes, as preliminary results show a more favorable response in TNBC, and to a lesser extent in ERþ breast cancer [83] , indicating that the immune response could differ according to subtypes. In addition, biomarkers predicting benefit from immunotherapy need to be identified. Although PD-L1 expression was used for eligibility in breast cancer trials thus far, its predictive value for the benefit from immunotherapy is unknown. Other immune parameters such as TILs may be candidate biomarkers [35] . The potential synergies between immunotherapy and existent therapies used in breast cancer should be explored. Close to 50 trials in immunotherapy are now open to breast cancer patients, many of which combine it with HER2-targeted therapy, chemotherapy, or endocrine therapy. Emerging information suggests that current immunotherapy approaches may be more effective in tumors with a higher mutational load. Strategies to increase the mutational load of certain tumors may actually expand the possibilities of immunotherapy. In addition, new imaging methodologies to correctly assess response to these agents are needed. Due to their extremely high cost, it is of paramount importance to assess the true value of this approach as well as to identify patients who will derive benefit from it.
Increase survivorship research efforts including supportive care and quality of life
The improvement in breast cancer prognosis in the last decades has resulted in an increasing number of survivors and a growing issue of survivorship. Indeed, with the 5-year survival rate estimated to be 80-90% in high-income countries [84] , it has become increasingly important to address breast cancer survivors' needs after completion of initial treatment. However, it is acknowledged that evidence is lacking to warrant strong, evidence-based recommendations on many issues of survivorship care [85] .
In order to fully address survivors' needs, different physical and psychosocial effects of breast cancer and its treatment must be taken into account, including depression, distress/anxiety, social disruption (personal and professional), barriers of return to work, sexuality, fertility, early menopausal symptoms, cognitive disorders, and second primaries. Furthermore, there is great heterogeneity and difficulty in predicting who will develop both medical and psychosocial long-term and late effects after treatment. Given the potential impact on both quantity and quality of life, the full impact of adjuvant therapies on the patients' lives need to be better defined. Improved rigorous databases and cohorts should be developed and supported to inform medical outcomes. Several QoL assessment tools exist, but few evaluate all the different aspects of QoL-psychological, social, physical and spiritual- [86] , and few have been specifically validated in the breast cancer population [87] . In addition, due to lack of clinical interpretation or difficulty in application, QoL results are seldom applied in clinical practice [88, 89] . To fill this gap, improved assessment or interpretation tools need to be developed. Guidelines to aid interpretation of QoL results may help ensure that available QoL results are actually used in clinical decision-making [90, 91] . In addition, as patients are discharged to primary care for follow-up and the survivorship period is prolonged, there is a need for better follow-up tools and guidance, for both patients and primary care physicians. Distance and online follow-up tools may provide solutions [92] [93] [94] , and their development and use should be strongly encouraged. Longterm follow-up is crucial since breast cancer has a very prolonged natural history. It does, however, pose important logistical issues and requires the implementation of new communication technologies allowing patients to directly provide their follow-up. Research into all aspects of optimal patient management and survivorship is important worldwide, including low-and middleincome countries [95, 96] . A major unmet need is the development of a specific QoL tool for advanced breast cancer patients to correctly ascertain the impact of new therapies. Furthermore, some advanced breast cancer patients, especially the HER2-positive subtype, can now live for 8 or 9 years and have specific survivorship issues that need close attention.
Of paramount importance are issues of availability and access to care, high-quality guidelines and their implementation as well as adequate ongoing education and training of all oncologists. These are issues common to the management of all malignancies and will not be discussed here.
Conclusions
The research priorities identified by the panel of experts reflect the evolution of breast cancer management in the last few decades and emerging medical needs, with increasing importance placed in the management of metastatic breast cancer, individually tailored treatment, and survivorship. It is the panel's opinion that these areas should receive sustained efforts in the coming years to see rapid progress.
